Plain-English translation of NCT06630923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether —a protein naturally found in blood—can help protect your kidneys when combined with standard water pills (diuretics) during heart failure treatment. Right now, doctors treat worsening heart failure with diuretics alone, but they worry about kidney damage. Researchers want to see if adding the medication to your diuretic therapy can prevent that kidney injury.
When people are hospitalized with severe heart failure, doctors give strong water pills to remove excess fluid from the body and lungs. Unfortunately, these medications can sometimes damage the kidneys as a side effect. This trial exists to find out whether this medication can protect kidney function while still treating the heart failure effectively.
You likely qualify if…
You likely don't qualify if…
You would be admitted to the hospital for your heart failure treatment as usual. Researchers would randomly assign you to receive either standard diuretic infusions alone, or diuretics combined with slow intravenous infusions of the medication being tested. During your hospital stay (at least 72 hours), medical staff would monitor your kidney function, blood pressure, and heart failure symptoms through blood tests and physical exams. Your participation ends when you are discharged from the hospital.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Greece